

## **Product datasheet for TP724822**

## OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## **Cynomolgus Recombinant Protein**

**Product data:** 

**Product Type:** Recombinant Proteins

**Description:** Recombinant Cynomolgus B7-1/CD80 (C-His)

Species: Cynomolgus
Expression cDNA Clone Val35-Asn242

or AA Sequence:

or AA Sequence.

Tag: C-6His

Buffer: Lyophilized from a 0.2 um filtered solution of PBS, 5% Trehalose pH 7.4

**Note:** Recombinant Cynomolgus T-lymphocyte Activation Antigen CD80 is produced by our

Mammalian expression system and the target gene encoding Val35-Asn242 is expressed with

a 6His tag at the C-terminus.

**Stability:** 12 months from date of despatch

Summary: CD80, also known as B7-1, is a member of cell surface immunoglobulin superfamily. CD80 is

predominately expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. CD80 and CD86, together with their receptors CD28 and CTLA4, form one of the dominant co-stimulatory pathways that mediate T- and B- cell responses. Although both CD28 and CTLA4 can bind to CD80 and CD86, CTLA-4 has 20-100 fold higher affinity than CD28 plays a role in the down-regulation of the immune response. CD80 is also involved in the induction of innate immune responses by activating NF-ΰB-signaling pathway in macrophages. Therefore, CD80 has the potential to be promising

therapeutic targets for autoimmune diseases and various carcinomas.

